704-705 / 2437
Conclusions
Improvement of radiotherapy safety, with promising efficacy in
patients with brain metastases
Well defined dose constraints (QUANTEC, ESTRO, RTOG)
New knowledge concerning the role of Neural Stem Cells
permitted to identify brain regions involved in plasticity and
repair processes (Hippocampus e.g.)
Randomized controlled trials have demonstrated significant
activity of Memantine and Donepezil for neurocognitive
impairment prevention, in patients treated with cranial
radiotherapy for primary and metastatic brain tumors
Even with new treatments (BEV e.g.) radiation necrosis
remains a challenge; better treatment for that is prevention